
Sign up to save your podcasts
Or


Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.
By Morgan Stanley4.8
12461,246 ratings
Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.

1,715 Listeners

977 Listeners

406 Listeners

1,173 Listeners

2,175 Listeners

198 Listeners

686 Listeners

1,044 Listeners

191 Listeners

70 Listeners

80 Listeners

1,574 Listeners

436 Listeners

212 Listeners

118 Listeners

81 Listeners

0 Listeners